Welcome to our dedicated page for CIBUS news (Ticker: CBUS), a resource for investors and traders seeking the latest updates and insights on CIBUS stock.
Company Overview
Cibus Inc is an agricultural biotechnology company specializing in the development and commercialization of advanced crop traits. Utilizing its proprietary Rapid Trait Development System (RTDS®), the company leverages cutting‐edge gene editing technologies to create and license plant traits that address critical challenges in modern farming. These include improved herbicide tolerance, enhanced disease resistance, optimized weed management, and better nutrient utilization, all of which contribute to increased productivity and sustainable farming practices.
Innovative Technology and Process
Cibus has revolutionized traditional breeding methodologies by introducing a highly efficient, high-throughput system that integrates crop-specific cell biology with sophisticated gene editing tools. The company’s technology allows for multiple gene modifications in a single developmental cycle—significantly reducing the time and cost associated with conventional breeding programs. This capability not only accelerates trait development but also ensures that the resultant genetic modifications are indistinguishable from those produced through natural processes, thereby positioning Cibus distinctively within the agricultural biotechnology landscape.
Business Model and Market Position
Unlike traditional seed companies, Cibus operates as a technology provider. Its core business model centers on developing novel crop traits and licensing them to seed companies, who then incorporate these traits into their breeding programs. This licensing model allows Cibus to generate revenue through royalties on seed sales, aligning its success with the productivity gains achieved by farmers worldwide. Emphasizing its industrialized approach to breeding, Cibus sets rigorous production standards that consistently deliver results in a predictable, time-bound manner.
Product Portfolio and Applications
The company’s robust portfolio includes multiple traits developed for major global row crops such as canola, rice, soybean, and others. Among its innovations are herbicide tolerance traits (such as HT1, HT2, and HT3) that provide farmers with additional tools for combating herbicide-resistant weeds, as well as traits designed to enhance resistance to significant crop diseases like Sclerotinia. These portfolio elements underscore Cibus’ commitment to addressing the productivity and sustainability challenges faced by modern agriculture.
Technological Integration and Collaborations
Cibus continues to push the boundaries of crop trait development through strategic collaborations. By partnering with leaders in artificial intelligence and machine learning, the company enhances its target discovery process, ensuring that its gene-editing efforts are both precise and scalable. These collaborations enable the identification of novel gene targets and streamline the application of complex edits, thereby reinforcing the company’s position as a pioneer in high-throughput gene editing.
Industry Impact and Expertise
Operating at the intersection of biotechnology and agriculture, Cibus provides a vital contribution to the farming sector by addressing issues that traditionally lead to significant economic losses. Through its innovative technology, the company plays a central role in modernizing plant breeding and delivering traits that can alleviate challenges such as pest infestations, plant diseases, and herbicide resistance. The scientific underpinnings of its RTDS® process not only embody a breakthrough in crop improvement but also exemplify the expertise and technical rigor that define Cibus’ approach to sustainable agriculture.
Conclusion
In summary, Cibus Inc stands out for its cutting-edge gene editing technology, streamlined trait development process, and strategic licensing model. Its comprehensive focus on enhancing crop resilience and yield through advanced plant trait innovations makes it a key player in the agricultural biotechnology industry. The company’s commitment to rapidly delivering impactful solutions underscores its potential as an instrumental force in addressing complex agricultural challenges.
Cibus (Nasdaq: CBUS), an agricultural biotechnology company specializing in proprietary gene editing technologies for plant trait development in seeds, has scheduled its fourth quarter 2024 financial results announcement for March 20, 2025, after market close.
The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss financial results and company updates. U.S. participants can dial +1-877-300-8521, while international participants can use +1-412-317-6026.
A replay will be available until April 3, 2025, accessible by dialing +1-844-512-2921 (U.S.) or +1-412-317-6671 (International) with passcode 10196898. The webcast and slides will be available on the company's investor website for 90 days after the event.
Cibus (NASDAQ: CBUS) announced promising results from controlled environment testing of its third mode of action (MOA) for Sclerotinia resistance trait in Canola. The company's proprietary Rapid Trait Development System™ (RTDS®) technology enables the Trait Machine™, a semi-automated precision breeding system.
The company has completed edits in four MOAs for Sclerotinia resistance in Canola, with ongoing field tests for two of them. Management expects to complete field and/or greenhouse tests on all four MOAs by year-end 2025. The development aims to help farmers preserve crop yields and reduce fungicide usage.
This novel approach using gene editing demonstrates potential for developing durable resistance to complex diseases more quickly compared to conventional breeding methods. The company anticipates that these traits could extend to other crops like Soybean, addressing challenges posed by climate-driven changes in crop diseases and their geographic distribution.
Cibus (NASDAQ: CBUS) announced significant leadership changes as part of its succession strategy. CEO Rory Riggs has stepped down, with President and COO Peter Beetham assuming the role of Interim CEO. Riggs will continue as Chairman of the Board of Directors, while Beetham maintains his director position.
The company, which specializes in developing and licensing plant traits to seed companies for royalties, will initiate a search for a permanent CEO, considering both internal and external candidates. Greg Gocal will continue as Chief Scientific Officer.
This transition comes at a pivotal moment as Cibus evolves from an agricultural trait development company to a commercial trait company, leveraging its proprietary Rapid Trait Development System™ (RTDS®) gene editing process. The Board expressed confidence in the leadership team's ability to execute commercial priorities during this transition period.
Cibus (NASDAQ: CBUS) has issued a significant correction regarding previously reported rice gene editing conversion rates. The company acknowledged that the previously announced rates of 10-25% in Rice have not been reconfirmed, citing high variability in conversion rate data from subsequent experiments.
Despite this setback, Cibus continues to advance its oligonucleotide directed mutagenesis (ODM) editing technologies to improve editing conversion rates across various crops. The company maintains confidence in its Rapid Trait Development System™ (RTDS®) to meet customer requirements for trait editing in their germplasm through a time-bound and predictable process.
Cibus (Nasdaq: CBUS), a leading agricultural biotechnology company specializing in proprietary gene editing technologies for seed trait development, has announced its participation in the upcoming Sidoti Micro Cap Conference. The company's presentation will be delivered by Co-Founders Rory Riggs (CEO and Chairman) and Peter Beetham (President and COO) on Thursday, January 23, 2025, at 1:45 p.m. ET (10:45 a.m. PT). The presentation will be accessible via webcast to registered participants.
Cibus Inc (NASDAQ: CBUS) has announced a $22.6 million registered direct offering of 9,040,000 shares of Class A Common Stock, including pre-funded warrants, priced at $2.50 per share. The offering includes warrants to purchase an additional 9,040,000 shares, exercisable at $2.50 per share upon stockholder approval, with a five-year expiration term.
The company will use the proceeds to fund development of productivity traits pipeline and working capital. The offering, expected to close around January 24, 2025, involves existing investors, including CEO Rory Riggs. Additionally, Cibus is amending terms for existing warrant holders, reducing exercise price from $10.00 to $2.50 per share and extending the termination date to five years post-offering.
Cibus (NASDAQ: CBUS) has announced significant breakthroughs in its proprietary RTDS gene editing process, establishing production standards that enable trait development in customer's elite germplasm within 12 months. The company has achieved standardization for traits in Rice (herbicide tolerance HT1 and HT3) and Canola (pod shatter reduction, herbicide tolerance HT2, and Sclerotinia resistance).
Key advances include improved cell biology technology, enhanced oligonucleotide directed mutagenesis (ODM) editing platform with conversion rates of 10-25% in Rice and up to 50% in Canola, and streamlined semi-automated regeneration processes. While missing its 2024 goal for an operational soybean platform, Cibus successfully edited Soybean cells with HT2 trait genetic changes.
The company's standardized process represents a significant shift from conventional breeding methods, offering a timebound and predictable system for trait development. These genetic changes are expected to be regulated similarly to naturally occurring traits, distinguishing them from GMOs.
Cibus (NASDAQ: CBUS) has affirmed its collaboration with RTDC and Albaugh to commercialize its Clethodim-tolerant HT-3 rice trait, a gene-edited weed management solution for U.S. rice farmers. The partnership combines Cibus' gene editing expertise with Albaugh's crop protection and market development capabilities.
The company has secured four seed partners for this trait - two in the United States and two in South America - and is in discussions with major rice seed companies in Asia. The HT-3 trait represents a breakthrough in herbicide tolerance technology and is expected to be the first of several stacked weed management traits in rice from Cibus.
Cibus (Nasdaq: CBUS) and Biographica have announced a collaborative pilot project to advance disease resistance in oilseed rape and Canola. The partnership combines Biographica's proprietary AI and machine learning platform for gene target identification with Cibus' expertise in crop trait development. Biographica will analyze gene targets associated with disease resistance, while Cibus will focus on developing crop varieties with enhanced resilience. The collaboration aims to identify multiple modes of action for developing durable disease resistance in plants, potentially accelerating the delivery of improved crop varieties to farmers worldwide.
Cibus (Nasdaq: CBUS), an agricultural technology company specializing in plant trait development and licensing, has announced its participation in the 13th Annual Roth Technology Conference. The event will take place in New York City on November 19-20, 2024. Rory Riggs, Co-Founder, CEO, and Chairman, will represent the company at the conference. Attendees interested in meeting with Cibus representatives during either day of the conference are encouraged to arrange appointments through their conference host representative or directly with the company.
FAQ
What is the current stock price of CIBUS (CBUS)?
What is the market cap of CIBUS (CBUS)?
What is the primary focus of Cibus Inc?
How does Cibus generate revenue?
What is the Rapid Trait Development System (RTDS®)?
How is Cibus' gene editing approach different from conventional methods?
What types of crop traits does Cibus develop?
Does Cibus manufacture seeds directly?
How do Cibus’ partnerships contribute to its innovation?
What benefits do seed companies gain from using Cibus’ traits?
